B Capital Group

Indian social commerce and e-commerce platform enabling small businesses, individual entrepreneurs, and resellers to sell products online through social channels. Originally a reseller network connecting suppliers with micro-entrepreneurs, evolved into a full consumer marketplace with 234 million annual transacting users.

Electric scooter and micromobility company that pioneered shared dockless electric scooters in cities. Bird deployed fleets of app-unlocked e-scooters and e-bikes across hundreds of cities globally. Became the fastest company in history to reach a $1B valuation. After going public via SPAC in 2021, filed Chapter 11 bankruptcy in December 2023. Assets sold to Third Lane Mobility in April 2024.

Humanoid robotics company building the Apollo general-purpose robot for manufacturing, logistics, and retail. Spun out of the University of Texas Human Centered Robotics Lab in 2016.

All-in-one operations and technology partner for independent food and beverage businesses, providing supply chain management, mobile ordering, and AI-powered tools. Odeko serves over 14,000 independent F&B businesses across the United States.

Technology-driven insurance brokerage that provides business insurance, employee benefits, and risk management services. Founded by former Opendoor and LinkedIn employees, Newfront combines software automation with deep insurance expertise to modernize how middle-market businesses purchase and manage commercial insurance.

AI-powered platform for verifiable code translation and optimization across programming languages and hardware systems. Uses neuro-symbolic AI combining large language models with formal verification methods to ensure provably correct translations for mission-critical industries including defense, aerospace, semiconductors, and automotive.

Clinical-stage precision oncology company that built a proprietary Predictive Precision Medicines Platform (PPMP) to bio-simulate cancer treatments and predict patient response. Originally tested combinations of FDA-approved drugs on patient cancer cell samples for blood cancers. Demonstrated 84% accuracy in predicting treatment responses with Stanford.